オプションチェーンは、Acelyrinの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Acelyrinの市場センチメントを評価します。.

Acelyrin (NASDAQ:SLRN) 株価情報, オプションチェーン

Acelyrin

Acelyrin Inc is a late-stage clinical biopharmaceutical company. It is focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating development and commercialization of of transformative medicines.

Acelyrin Inc

Derek Archila, an analyst from Wells Fargo, maintained the Buy rating on ACELYRIN, INC. (SLRN – Research Report). The associated price target remai...

Promising Phase 1/2 Results for ACELYRIN's Lonigutamab Support Buy Rating

In a report released today, Tyler Van Buren from TD Cowen maintained a Buy rating on ACELYRIN, INC. (SLRN – Research Report). The company's shares ...

ACELYRIN, INC. (SLRN) Receives a Buy from TD Cowen

Acelyrin falls after updating mid-stage trial data for eye disease drug

Citi lowered the firm's price target on Acelyrin (SLRN) to $3 from $6 and keeps a Neutral rating on the shares after the company presented Phase 1b...

Acelyrin price target lowered to $3 from $6 at Citi

09:21 EST Acelyrin (SLRN) sinks 39% to $2.12 after thyroid eye disease data update Published first on TheFly – the ultimate source for real-time, m...

Acelyrin sinks 39% to $2.12 after thyroid eye disease data update

Wedbush is not changing the firm's positive bias on Viridian Therapeutics (VRDN) after its competitor Acelyrin (SLRN) hosted an investor event to d...

Wedbush stays positive on Viridian shares after Acelyrin data

H.C. Wainwright lowered the firm's price target on Acelyrin (SLRN) to $6 from $8 and keeps a Neutral rating on the shares. During the call yesterda...

Acelyrin price target lowered to $6 from $8 at H.C. Wainwright

ACELYRIN, INC. (SLRN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Vikram Purohit fr...

Cautious Hold Rating for ACELYRIN, INC. Amid Uncertainties in Lonigutamab's Efficacy and Dosing

MoonLake Immunotherapeutics: Mid-2025 Sonelokimab HS Data Could Be Enhanced Upon

ACELYRIN, INC. ( ($SLRN) ) has provided an announcement. On January 31, 2025, ACELYRIN, INC., a biopharmaceutical company, terminated its License a...

ACELYRIN, INC. Ends Key Agreement with Affibody

MLTX

NVSEF

SLRN

VRDN

Earnings

Health Care

Press Releases

ACELYRIN, INC. Announces Positive Phase 3 Data for Izokibep in Hidradenitis Suppurativa; Focuses Strategy on Lonigutamab and Reports Second Quarter 2024 Financial Results

News

ACELYRIN, INC. to Participate in Upcoming Investor Conferences

ACELYRIN, INC. Announces Positive Proof-of-Concept Data From Phase 1/2 Clinical Trial of Lonigutamab as a Subcutaneous Treatment for Thyroid Eye Disease to be Presented at 42nd Annual Meeting of European Society of Ophthalmic Plastic and Reconstructive Surgery

ACELYRIN, INC. Announces Positive Results from Global Phase 3 Clinical Trial of Izokibep in Hidradenitis Suppurativa to be Highlighted in Late-Breaking Oral Presentation at EADV 2024

ACELYRIN, INC. Forms Scientific and Patient Advisory Board Featuring Leading Voices in Thyroid Eye Disease

ACELYRIN, INC. to Report Third Quarter 2024 Financial Results and Corporate Update on November 13, 2024

ACELYRIN, INC. Reports Third Quarter 2024 Financial Results and Recent Highlights

ACELYRIN, INC. Announces Topline Results From Phase 2b/3 Study of Izokibep for the Treatment of Uveitis

ACELYRIN, INC. to Host Virtual Investor Event to Share new Phase 2 Data and Phase 3 Program Design for Subcutaneous Lonigutamab

ACELYRIN, INC. Announces Additional Phase 2 Data and Phase 3 Program Design for Lonigutamab in Thyroid Eye Disease

Acrivon Therapeutics, Inc. - Common Stock

Acrivon Therapeutics

Actuate Therapeutics, Inc. - Common stock

Actuate Therapeutics

Alector

Amarin Corporation plc - American Depositary Shares, each representing one Ordinary Share

Amarin Corp

Perspective Therapeutics, Inc. Common Stock

Perspective Therapeutics

C4 Therapeutics

Cidara Therapeutics

Cargo Therapeutics

Foghorn Therapeutics

Genfit

Gossamer Bio

TuHURA Biosciences

Inhibrx Biosciences

INmune Bio

Larimar Therapeutics, Inc. - Common Stock

Larimar Therapeutics

Lexeo Therapeutics

Lyell Immunopharma

Macrogenics

Molecular Partners AG - American Depositary Shares

Molecular Partners

Ocugen

Protalix BioTherapeutics, Inc. (DE) Common Stock

Protalix BioTherapeutics

ProKidney Corp. - Class A Ordinary Shares

ProKidney

Sera Prognostics, Inc. - Class A Common Stock

Sera Prognostics

Protara Therapeutics, Inc. - Common Stock

Comments

Acelyrin

Acelyrin (SLRN) オプション

No option chain data available. Please try again later

ニュース

パートナーシップ

ベンジンガ・グローバル